(Reuters) -Bristol Myers Squibb said on Monday its experimental drug to treat a type of heart disease did not meet the main goals in a late-stage study.
The drug, mavacamten, was being tested in adult patients with the so-called non-obstructive form of hypertrophic cardiomyopathy, an inherited condition characterized by thickening of heart muscles.
The New York-based company’s shares fell 2.4% in extended trading.
The drug, branded as Camzyos, is already approved in the U.S. for the obstructive form of the disease, which could block blood flow out of the heart.
The company said it plans to share detailed trial results with the scientific community in the future.
(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona)
Brought to you by www.srnnews.com
